DakoCytomation Granted License to Cancer Diagnostic

(Research Triangle Park, NC, USA). The license covers all patents and the hybridoma that produces the antibody.

While studying the basal lamina, BioStratum's collaborating researchers at the Karolinska Institute (Stockholm, Sweden) discovered that laminin-5 is involved in the migration of most epithelial cells as well as epithelial-cell-derived cancers. The degree to which a tissue biopsy stains with MetaStain, a monoclonal antibody that binds to the gamma-2 chain of laminin-5, was shown to predict a cancer's invasive potential and/or metastatic potential.

"We will develop a diagnostic test that can predict the aggressiveness of a cancer, which is very important since cancer is not a single disease but many, and comes in various disguises. This will allow a more targeted treatment for the patient, thus improving the outcome,” said Jes Ostergaard, president and CEO of DakoCytomation.





Related Links:
DakoCytomation
BioStratum